Instinct’s $250M Series B at $2.5B: Consumer Agents Hit Mega-Round Speed
Index Ventures and Benchmark co-led Instinct’s $250M Series B at a $2.5B valuation — total funding ~$350M for a private-beta life-ops agent still weeks old as a viral product.
index-ventures — Venture Capital Articles & Research
Explore our latest articles on index-ventures — covering venture capital deals, fund activity, startup fundraising strategy, and investor research relevant to this topic.
Whether you're a founder building an investor target list, an analyst tracking deal flow, or an operator researching market trends, the articles below provide practical, up-to-date venture capital intelligence.
Why This Topic Matters in VC
- Deal flow signal: Funding activity and investor conviction in index-ventures
- Fundraising context: Which investors are active and what traction they expect
- Market timing: Sector momentum, valuation benchmarks, and competitive dynamics
Browse all index-ventures articles below, or use our investor list to research active investors by stage and sector.
Related Articles (5 articles)
-
-
Aug 8 Investment News Batch: Fireworks, Wonder, Ambrook + Bessemer Cyber Cluster
Gap-fill coverage for late-July / early-August 2026 deals not already in earlier roundups — specialized AI inference, food-tech growth, real-economy fintech, and Bessemer’s agentic security stack.
-
Index Leads Intelligence’s $7.9M Seed: Human Taste as AI Eval Infra
Index Ventures led Intelligence’s $7.9M seed for Design Arena — a human preference platform that frontier labs pay for to improve visual/media models.
-
Fireworks AI’s $1.5B Series D at $17.5B: Specialized Intelligence Hits $1B ARR
Index Ventures co-led Fireworks AI’s $1.505B Series D at a $17.5B valuation in July 2026 as the PyTorch-founded inference platform crossed $1B ARR — with Bessemer, Menlo, and Insight among participants.
-
Chai Discovery's $400M Series C at $3.8B: Index, Kleiner, Sequoia Bet on AI Molecules
Index Ventures led Chai Discovery's $400M Series C at $3.8B as Eli Lilly, Novartis, and Pfizer put AI-designed molecules into real discovery pipelines.